课题基金 / 基金详情

Contraceptive Services/Primary Care to Prevent Birth Defects

Contraceptive Services/Primary Care to Prevent Birth Defects
预防出生缺陷的避孕服务/初级保健
批准号:
7932196
负责人:
ELEANOR Bimla SCHWARZ
金额:
$12.62万
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-08-09 至 2012-01-31

项目摘要

项目成果

ELEANOR Bimla SCHWARZ的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Each year, 150,000 infants (1% - 3% of all U.S. births) are born with some form of physical or mental birth defect. As it is sometimes necessary to treat women with medications that cause birth defects, physicians must counsel women about medication risks and contraceptive options. In a recent analysis of the 1998-2000 National Ambulatory Medical Care Surveys, I found that generalist physicians provide ambulatory care to 45% of women using potentially teratogenic medications, but rarely (less than 20% of the time) provide contraceptive counseling. The reasons why many generalist physicians do not provide this counseling are not known. I seek a K23 award to strengthen my abilities to develop effective interventions to prevent birth defects resulting from inappropriate use of teratogenic medications by women of childbearing age. Specifically, I propose to conduct a retrospective cohort study of 650,000 women of reproductive age served by Northern California Kaiser Permanente pharmacies to identify which potentially teratogenic medications are most frequently prescribed without use of highly effective contraception (Aim 1); to conduct a cross sectional study of gaps in knowledge of primary care physicians that may contribute to unsafe prescription of teratogenic medications (Aim 2); and to evaluate the effect of a previously implemented clinic-based intervention to increase physician awareness of patients' contraceptive practices on unsafe prescription of teratogenic medications among approximately 190,000 women of childbearing age (Aim 3). To achieve these aims, I have assembled a mentoring committee whose expertise spans the relevant disciplines of epidemiology and general medicine (Drs. Grady and Gonazales) and gynecology (Dr. Darney). In addition, I have scientific advisors with expertise in reproductive epidemiology (Dr. Carmichael), reproductive social science (Dr. Joffe), patient safety (Dr. Wachter), survey instrument design (Dr. Stewart), biostatistics (Dr.Vittinghoff), risk assessment (Dr. Bindman), and use of the Kaiser Permanente databases (Dr. Shaber).Their mentorship, as well as a focused training and research plan facilitated by a K23 award, will enable me to achieve my goal of developing an independent career in patient-oriented clinical research, focused on facilitating contraceptive service provision to limit adverse birth outcomes, while furthering the NICHD's mission of ensuring that every person is born healthy and wanted.
期刊论文(27)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1016/j.contraception.2011.07.002
发表时间: 2011-12-01
期刊: Contraception
影响因子: 2.9
作者: [Gariepy, Aileen M, Simon, Erica J, Schwarz, Eleanor B]
通讯作者: Schwarz, Eleanor B
Contraceptive Counseling and Use among Women with Poorer Health.
健康状况较差的妇女的避孕咨询和使用。
DOI: 10.4172/2325-9795.1000103
发表时间: 2013
期刊: Journal of women's health, issues & care
影响因子: --
作者: [Lee,JessicaK, Parisi,SaraM, Schwarz,EleanorBimla]
通讯作者: Schwarz,EleanorBimla
Risk of hypospadias in offspring of women using loratadine during pregnancy: a systematic review and meta-analysis.
妊娠期间使用氯雷他定的妇女后代尿道下裂的风险:系统评价和荟萃分析。
DOI: 10.2165/00002018-200831090-00006
发表时间: 2008
期刊: Drug safety
影响因子: 4.2
作者: [Schwarz,EleanorB, Moretti,MylaE, Nayak,Smita, Koren,Gideon]
通讯作者: Koren,Gideon
DOI: 10.1007/s10995-011-0758-0
发表时间: 2012-02
期刊: Maternal and child health journal
影响因子: 2.3
作者: [McClure CK, Catov J, Ness R, Schwarz EB]
通讯作者: Schwarz EB
11
    Disseminating PCOR findings to Reduce Racial Disparities in Surgical Sterilization
    Improving the Safe Use of Isotretinoin
    Improving the Safe Use of Isotretinoin
    Harnessing Health IT to Prevent Medication-Induced Birth Defects
    国内基金
    海外基金
    补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
    靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
    • 批准号:
      JCZRQN202500010
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2025
    • 负责人:
    • 依托单位:
    对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
    • 批准号:
      2025JJ70209
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2025
    • 负责人:
      雷芬芳
    • 依托单位:
    AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
    • 批准号:
      --
    • 项目类别:
      面上项目
    • 资助金额:
      --
    • 批准年份:
      2024
    • 负责人:
      万荣
    • 依托单位: